FLT Stock Recent News

Generated revenue of $5,713,158 in Q1 2025 Achieved 30% EBITDA improvement over Q1 2024 Continuation of optimization efforts post Volatus and Drone Delivery Canada merger of equals Subsequent to quarter end, closed $3,000,000 fully subscribed LIFE Offering Subsequent to quarter end, announced closing of shares for debt transaction of $2,646,000 and an additional $446,400, strengthening balance sheet Volatus will host a webinar and live Q&A on Monday, June 2, 2025, at 8 am ET (see registration link below). TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the three months ended March 31, 2025 (Q1 2025).

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A2JEQU) (“Volatus” or the “Company”), a leader in global aerial solutions, is pleased to announce a proposed shares-for-debt settlement aimed at enhancing shareholder value and strengthening the Company's balance sheet. The Company has reached an agreement, subject to receipt of TSX Venture Exchange (“TSXV”) approval, with holders of unsecured non-convertible debentures of Volatus Aerospace Corp., a wholly-owned subsidiary of the Company (the “Debentures”), to settle the outstanding principal and accrued and unpaid interest owing under the Debentures as at the maturity date, being May 23, 2025, in the aggregate amount of $446,400 in consideration for the issuance of an aggregate of 3,720,000 units of the Company (the “Settlement Units”) at a deemed price of $0.12

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: ABB) ("Volatus" or the “Company"), a leader in global aerial solutions, is pleased to announce that, further to its press release dated April 11, 2025, the Company has completed its previously announced shares-for-debt transaction (the “Shares-for-Debt Transaction”) and issued a total of 20,174,280 common voting shares in the capital of the Company (the “Common Shares”) and 17,640,000 Common Share purchase warrants (each a “Warrant”) settling an aggregate debt of $3,026,142.00 owing to holders of unsecured convertible debentures of the Company (the “Debentures”) issued pursuant to a debenture indenture dated May 11, 2023 between the Company and TSX Trust Company. To give effect to the Shares-for-Debt Transaction, the Company and TSX Trust Company, as trustee, entere

Video illustrates SENTI-202's MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit Video illustrates SENTI-202's MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the twelve-month period and fourth quarter ended Dec 31, 2024 (“FY 2024” and “Q4 2024”, respectively). All dollar figures are stated in Canadian dollars, unless otherwise indicated.

Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has filed an offering document in connection with a non-brokered private placement of up to 16,666,667 units of the Company (the “Units”) at a price of $0.12 per Unit (the “Issue Price”) for gross proceeds of up to $2,000,000.04 (the “LIFE Financing”).

Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies Actimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCI NEW YORK , April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone the

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort 4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; Register Here Announces certain preliminary first quarter 2025 financial results and provides pipeline update SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company?

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A3DP5Y/ABBA.F) is pleased to announce that last week it was approved by two leading North American oil and gas companies to provide drone-based aerial services in support of critical energy infrastructure. This approval follows a comprehensive flight operations review process conducted to validate Volatus' operational readiness and safety protocols.

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A2JEQU) ("Volatus" or the “Company"), a leader in global aerial solutions, is pleased to announce a proposed shares-for-debt settlement aimed at enhancing shareholder value and strengthening the Company's balance sheet. Effective April 10, 2025, the Company has reached an agreement, subject to receipt of TSX Venture Exchange (“TSXV”) approval, with the holders of convertible debentures issued pursuant to a debenture indenture dated May 11, 2023 (the “Debenture Indenture”) between the Company and TSX Trust Company as trustee (the “Trustee”).